Novo Nordisk's Oral Weight-Loss Pill Approval Boosts Shares

Novo Nordisks new weight-loss pill approved by FDA, boosting shares by nearly ten percent in Frankfurt. The oral medication gives Novo a competitive edge over rival Eli Lilly, potentially attracting patients who prefer tablets over shots. Novos shares, which have dropped over fifty percent this year, may see a rebound as investors bet on the companys renewed dominance in the weight-loss market.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.